Chronic Lymphocytic Leukemia Treatment of CLL, the most common leukemia in the West,
has undergone a revolution in the past few years with the development of agents that target …

The somatic hypermutation (SHM) status of the clonotypic immunoglobulin heavy variable
(IGHV) gene is a critical biomarker for assessing the prognosis of patients with chronic …

Since the publication of the Revised European-American Classification of Lymphoid
Neoplasms in 1994, subsequent updates of the classification of lymphoid neoplasms have …

Recent advances in cancer characterization have consistently revealed marked
heterogeneity, impeding the completion of integrated molecular and clinical maps for each …

With the introduction of large-scale molecular profiling methods and high-throughput
sequencing technologies, the genomic features of most lymphoid neoplasms have been …

Chronic lymphocytic leukemia (CLL) is characterized by the existence of subsets of patients
with (quasi) identical, stereotyped B-cell receptor (BcR) immunoglobulins. Patients in certain …

Chronic lymphocytic leukemia is a well-defined lymphoid neoplasm with very
heterogeneous biological and clinical behavior. The last decade has been remarkably …

The concept of precision cell therapy targeting tumor-specific mutations is appealing but
requires surface-exposed neoepitopes, which is a rarity in cancer. B cell receptors (BCR) of …

Vaccine-induced immune thrombotic thrombocytopenia (VITT) is a rare thromboembolic
complication of adenoviral-vectored SARS-CoV2 vaccines, mediated by antibodies directed …

B-cell receptor (BCR) signaling is crucial for chronic lymphocytic leukemia (CLL) biology.
IGLV3-21–expressing B cells may acquire a single point mutation (R110) that triggers …